The estimated Net Worth of Daniel Hume is at least $1.67 Milione dollars as of 12 February 2020. Mr. Hume owns over 33,656 units of TG Therapeutics Inc stock worth over $1,433,824 and over the last 8 years he sold TGTX stock worth over $0. In addition, he makes $235,000 as Independent Director at TG Therapeutics Inc.
Sign up
Mr. Hume TGTX stock SEC Form 4 insiders trading
Daniel has made over 1 trades of the TG Therapeutics Inc stock since 2020, according to the Form 4 filled with the SEC. Most recently he exercised 33,656 units of TGTX stock worth $776,444 on 12 February 2020.
The largest trade he's ever made was exercising 33,656 units of TG Therapeutics Inc stock on 12 February 2020 worth over $776,444. On average, Daniel trades about 1,771 units every 0 days since 2016. As of 12 February 2020 he still owns at least 62,151 units of TG Therapeutics Inc stock.
You can see the complete history of Mr. Hume stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Daniel Hume biography
Daniel Hume serves as Independent Director of the Company. Mr. Hume is currently a managing partner at Kirby McInerney, LLP. Mr. Hume’s law practice focuses on securities law regulation, structured finance, antitrust, and civil litigation. Mr. Hume is member of the board of directors of Stemline Therapeutics Inc. (Nasdaq: STML), a late clinical stage biopharmaceutical company, and National Holdings Corporation (Nasdaq: NHLD), a financial services company. Mr. Hume is admitted to the New York State Bar and federal courts around the country, including the United States Supreme Court. Mr. Hume received a B.A. in philosophy and graduated magna cum laude from the State University of New York at Albany, and earned a J.D. from the Columbia University Law School, where he served as Notes Editor for the Columbia Journal of Environmental Law.
What is the salary of Daniel Hume?
As the Independent Director of TG Therapeutics Inc, the total compensation of Daniel Hume at TG Therapeutics Inc is $235,000. There are 6 executives at TG Therapeutics Inc getting paid more, with Michael Weiss having the highest compensation of $12,674,700.
How old is Daniel Hume?
Daniel Hume is 53, he's been the Independent Director of TG Therapeutics Inc since 2015. There are 6 older and 2 younger executives at TG Therapeutics Inc. The oldest executive at TG Therapeutics Inc is William Kennedy, 75, who is the Independent Director.
What's Daniel Hume's mailing address?
Daniel's mailing address filed with the SEC is 3020 CARRINGTON MILL BLVD, SUITE 475, , MORRISVILLE, NC, 27560.
Insiders trading at TG Therapeutics Inc
Over the last 13 years, insiders at TG Therapeutics Inc have traded over $23,556,837 worth of TG Therapeutics Inc stock and bought 549,710 units worth $3,334,566 . The most active insiders traders include Capital Management, L.P.Kol..., Michael S Weiss e Sean A Power. On average, TG Therapeutics Inc executives and independent directors trade stock every 107 days with the average trade being worth of $1,103,023. The most recent stock trade was executed by Sagar Lonial on 17 June 2024, trading 25,933 units of TGTX stock currently worth $432,822.
What does TG Therapeutics Inc do?
tg therapeutics is a biopharmaceutical company focused on the acquisition, development and commercialization of novel treatments for b-cell malignancies and autoimmune diseases. currently, the company is developing two therapies targeting hematological malignancies. tg-1101 (ublituximab) is a novel, glycoengineered monoclonal antibody that targets a specific and unique epitope on the cd20 antigen found on mature b-lymphocytes. tg therapeutics is also developing tgr-1202, an orally available pi3k delta inhibitor. the delta isoform of pi3k is strongly expressed in cells of hematopoietic origin and is believed to be important in the proliferation and survival of b-lymphocytes. both tg-1101 and tgr-1202 are in clinical development for patients with hematologic malignancies. the company also has pre-clinical programs to develop irak4 inhibitors, and anti-pd-l1 and anti-gitr antibodies. tg therapeutics is headquartered in new york city and is traded on nasdaq under the ticker symbol "tgtx".
What does TG Therapeutics Inc's logo look like?
Complete history of Mr. Hume stock trades at National, Stemline Therapeutics e TG Therapeutics Inc
TG Therapeutics Inc executives and stock owners
TG Therapeutics Inc executives and other stock owners filed with the SEC include:
-
Michael Weiss,
Executive Chairman of the Board, President, Chief Executive Officer -
Michael S. Weiss Esq.,
Chairman, CEO & Pres -
Sean Power,
Chief Financial Officer, Treasurer, Corporate Secretary -
Sean A. Power CPA, CPA,
CFO, Corp. Sec. & Treasurer -
Laurence Charney,
Independent Director -
Kenneth Hoberman,
Independent Director -
William Kennedy,
Independent Director -
Daniel Hume,
Independent Director -
Yann Echelard,
Independent Director -
Jenna Bosco,
Senior Vice President - Corporate Communications -
Sagar Lonial,
Independent Director -
Kelly Ross,
Chief Technology Officer -
Adam Waldman,
Chief Commercial Officer -
Dr. Owen A. O'Connor,
Chief Scientific Officer -
Biotechnologies S.A.S.U. Lfb,
10% owner -
Mark Schoenebaum,
Director -
Neil Herskowitz,
Director -
Capital Management, L.P.Kol...,